Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 1002 for:    BMD

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02760264
Recruitment Status : Completed
First Posted : May 3, 2016
Results First Posted : January 1, 2019
Last Update Posted : January 1, 2019
Sponsor:
Collaborators:
University of Pittsburgh
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Neurological Disorders and Stroke (NINDS)
Cooperative International Neuromuscular Research Group
Information provided by (Responsible Party):
ReveraGen BioPharma, Inc.

Tracking Information
First Submitted Date  ICMJE April 28, 2016
First Posted Date  ICMJE May 3, 2016
Results First Submitted Date  ICMJE September 28, 2018
Results First Posted Date  ICMJE January 1, 2019
Last Update Posted Date January 1, 2019
Study Start Date  ICMJE June 2016
Actual Primary Completion Date May 1, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 11, 2018)
Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03 [ Time Frame: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration. ]
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug. Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group
Original Primary Outcome Measures  ICMJE
 (submitted: April 30, 2016)
Number of participants with treatment-related adverse events as assessed by CTCAE Version 4.03. [ Time Frame: 4 weeks ]
Change History Complete list of historical versions of study NCT02760264 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: December 11, 2018)
  • Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose [ Time Frame: Baseline, Week 2 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose [ Time Frame: Baseline, Week 2 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin [ Time Frame: Baseline , Week 2 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin [ Time Frame: Baseline, Week 2 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol [ Time Frame: Week 2 (pre-dose) ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin [ Time Frame: Baseline, Day 1, Week 2, Week 4 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide [ Time Frame: Baseline Day 1 Week 2 Week 4 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide [ Time Frame: Baseline, Day 1, Week 2, Week 4 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides [ Time Frame: Baseline, Day 1, Week 4 ]
    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD.
  • Pharmacokinetic (PK) Assessments (Tmax) [ Time Frame: Day 1, Week 2 ]
    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.
  • Pharmacokinetic (PK) Assessments (AUC Inf) [ Time Frame: Day 1, Week 2 ]
    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.
  • Pharmacokinetic (PK) Assessments CL (ml/hr/kg) [ Time Frame: Day 1, Week 2 ]
    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
  • Pharmacokinetic (PK) Assessments t(1/2) [ Time Frame: Day 1, Week 2 ]
    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.
  • Pharmacokinetic (PK) Assessments (Cmax) [ Time Frame: Day 1, Week 2 ]
    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
  • Metabolites in Safety Testing (MIST) Assessment [ Time Frame: Week 2 (Day 14) ]
    A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 30, 2016)
  • Peak plasma concentration (Cmax) of vamorolone [ Time Frame: Day 1 ]
  • Peak plasma concentration (Cmax) of vamorolone [ Time Frame: Week 2 ]
  • Serum pharmacodynamics biomarkers measured by levels of cortisol, ACTH, PINP, osteocalcin, CTX, 17-hydroxyprogesterone, testosterone, corticosterone, 11-deoxycortisol, glucose and insulin [ Time Frame: Week 2 ]
  • Serum metabolites of vamorolone [ Time Frame: Week 2 ]
    Metabolites in Safety Testing (MIST)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures
 (submitted: April 30, 2016)
  • Muscle strength measured by Quantitative Muscle Testing (QMT) [ Time Frame: 4 weeks ]
  • Muscle function measured by Time to Stand Test (TTSTAND) [ Time Frame: 4 weeks ]
  • Muscle function measured by Time to Climb Test (TTCLIMB) [ Time Frame: 4 weeks ]
  • Muscle function measured by Time to Run/Walk 10 Meters Test (TTRW) [ Time Frame: 4 weeks ]
  • Muscle function measured by North Star Ambulatory Assessment (NSAA) [ Time Frame: 4 weeks ]
  • Muscle function measured by Six-minute Walk Test (6MWT) [ Time Frame: 4 weeks ]
 
Descriptive Information
Brief Title  ICMJE A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Official Title  ICMJE A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Brief Summary The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
Detailed Description This study will evaluate the safety and tolerability of a new steroid-like medication called vamorolone in boys with DMD ages ≥ 4 years and < 7 years. Enrolled participants will take the study medication for 14 days followed by a 14 day follow-up period. The potential effectiveness of vamorolone in treating DMD will also be explored.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Duchenne Muscular Dystrophy
Intervention  ICMJE
  • Drug: Vamorolone 0.25 mg/kg/day
    Oral administration of 0.25 mg/kg/day daily for 14 days.
    Other Name: VBP15
  • Drug: Vamorolone 0.75 mg/kg/day
    Oral administration of 0.75 mg/kg/day daily for 14 days.
    Other Name: VBP15
  • Drug: Vamorolone 2.0 mg/kg/day
    Oral administration of 2.0 mg/kg/day daily for 14 days.
    Other Name: VBP15
  • Drug: Vamorolone 6.0 mg/kg/day
    Oral administration of 6 mg/kg/day daily for 14 days.
    Other Name: VBP15
Study Arms  ICMJE
  • Experimental: Dose Level Group 1
    Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
    Intervention: Drug: Vamorolone 0.25 mg/kg/day
  • Experimental: Dose Level Group 2
    Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
    Intervention: Drug: Vamorolone 0.75 mg/kg/day
  • Experimental: Dose Level Group 3
    Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
    Intervention: Drug: Vamorolone 2.0 mg/kg/day
  • Experimental: Dose Level Group 4
    Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
    Intervention: Drug: Vamorolone 6.0 mg/kg/day
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 7, 2016)
48
Original Estimated Enrollment  ICMJE
 (submitted: April 30, 2016)
30
Actual Study Completion Date  ICMJE May 1, 2018
Actual Primary Completion Date May 1, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject's parent or legal guardian has provided written informed consent/Health Insurance Portability and Accountability Act (HIPAA) authorization prior to any study-related procedures;
  2. Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:

    1. Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR
    2. Identifiable mutation within the DMD gene (deletion/duplication of one or more exons) where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, OR
    3. Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein (i.e. nonsense mutation, deletion/duplication leading to a downstream stop codon), with a typical clinical picture of DMD;
  3. Subject is ≥ 4 years and < 7 years of age at time of enrollment in the study;
  4. Subject is able to complete the Time to Stand Test (TTSTAND) without assistance, as assessed at the Screening and Baseline Visits;
  5. Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not clinically significant, in the opinion of the Investigator. (Note: Serum gamma glutamyl transferase [GGT], creatinine, and total bilirubin all must be ≤ upper limit of the normal range at the Screening Visit);
  6. Subject has evidence of chicken pox immunity as determined by presence of IgG antibodies to varicella, as documented by a positive test result from the testing laboratory at the Screening Visit; and
  7. Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.

Exclusion Criteria:

  1. Subject has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;
  2. Subject has current or history of chronic systemic fungal or viral infections;
  3. Subject has had an acute illness within 4 weeks prior to the first dose of study medication;
  4. Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;
  5. Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary];
  6. Subject is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents. [Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
  7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;
  8. Subject has an allergy or hypersensitivity to the study medication or to any of its constituents;
  9. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
  10. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;
  11. Subject is taking any other investigational drug currently or has taken any other investigational drug within 3 months prior to the start of study treatment; or
  12. Subject has previously been enrolled in the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Ages  ICMJE 4 Years to 6 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   Israel,   Sweden,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02760264
Other Study ID Numbers  ICMJE VBP15-002
1R44NS095423-01 ( U.S. NIH Grant/Contract )
1U34AR068616-01 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party ReveraGen BioPharma, Inc.
Study Sponsor  ICMJE ReveraGen BioPharma, Inc.
Collaborators  ICMJE
  • University of Pittsburgh
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • Cooperative International Neuromuscular Research Group
Investigators  ICMJE
Study Chair: Paula R Clemens, MD University of Pittsburgh
PRS Account ReveraGen BioPharma, Inc.
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP